Zeelab Pharmacy, founded by Rohit Mukul, is aiming to reach ₹200 crore in revenue in fiscal year 2027, building on its ₹110 crore operating revenue in FY26. The company, which began operations in April 2020, has grown to operate over 300 stores and processes about 10,000 orders daily, balancing online and offline sales channels, according to inc42.com.
Mukul’s approach to affordable medicines stems from his studies at the London School of Economics and his analysis of India’s pharmaceutical supply chain. He identified that multiple intermediaries inflate medicine prices significantly, with a ₹10 medicine often costing ₹100 by the time it reaches consumers. Zeelab’s model cuts out these middlemen to offer lower prices, a strategy that has driven its growth over six years, inc42.com reports.
The Indian pharmaceutical market has long faced challenges with price inflation due to complex supply chains. Zeelab’s model addresses this by simplifying distribution and focusing on affordability, which differentiates it from many competitors. Its growth to 300 stores and balanced online-offline presence reflects a shift in consumer access to affordable medicines, a sector where price sensitivity is critical, as noted by inc42.com.
Zeelab’s next milestone is to double its operating revenue from ₹110 crore in FY26 to ₹200 crore in FY27, demonstrating significant scaling of its affordable pharma business. The company’s daily order volume of around 10,000 and extensive retail footprint underpin this target, according to inc42.com.